Contrasting echogenicity in flexor digitorum profundus-flexor carpi ulnaris: A diagnostic ultrasound pattern in sporadic inclusion body myositis

2014 ◽  
Vol 49 (5) ◽  
pp. 745-748 ◽  
Author(s):  
Yu-Ichi Noto ◽  
Kensuke Shiga ◽  
Yukiko Tsuji ◽  
Masaki Kondo ◽  
Takahiko Tokuda ◽  
...  
Keyword(s):  
Inclusion Body ◽  
Inclusion Body Myositis ◽  
Diagnostic Ultrasound ◽  
Flexor Digitorum Profundus ◽  
Flexor Carpi Ulnaris ◽  
Sporadic Inclusion Body Myositis ◽  
Flexor Digitorum

Electromyographs of the flexor digitorum profundus muscle are useful for the diagnosis of inclusion body myositis

2012 ◽  
Vol 46 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Keiichi Hokkoku ◽  
Masahiro Sonoo ◽  
Mana Higashihara ◽  
Erik Stålberg ◽  
Teruo Shimizu
Keyword(s):  
Inclusion Body ◽  
Inclusion Body Myositis ◽  
Flexor Digitorum Profundus ◽  
Flexor Digitorum ◽  
Flexor Digitorum Profundus Muscle

scholarly journals SAT0332 ANTIBODIES AGAINST CYTOSOLIC 5’-NUCLEOTIDASE 1A IN SPORADIC INCLUSION BODY MYOSITIS: ASSOCIATION WITH CLINICAL AND MRI FEATURES

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1112.1-1112
Author(s):  
R. Dejthevaporn ◽  
S. Shah ◽  
S. Wastling ◽  
J. Thornton ◽  
T. Yousry ◽  
...  
Keyword(s):  
Inclusion Body ◽  
Inclusion Body Myositis ◽  
Rating Scale ◽  
Fatty Infiltration ◽  
Connective Tissue Diseases ◽  
Diagnostic Process ◽  
Antibody Testing ◽  
Muscle Mri ◽  
Mri Features ◽  
Sporadic Inclusion Body Myositis

Background:Autoantibodies directed against cytosolic 5´-nucleotidase 1A (cN1A) have been identified in sporadic inclusion body myositis (sIBM) and other connective tissue diseases. Anti-cN1A antibodies may support the diagnostic process for sIBM as well as potentially provide clues for disease pathogenesis. Nevertheless, the utility of anti-cN1A autoantibody testing in clinical practice remains unclear and requires validation.Objectives:To investigate the association between anti-cN1A antibody status and clinical and MRI features in patients with sIBM.Methods:Data for patients fulfilling European Neuromuscular Centre (ENMC) 2011 criteria for sIBM were obtained from a natural history study database. Demographic, clinical, functional assessment, and muscle MRI data in patients with sIBM who had anti-cN1A autoantibody testing were collected and analysed. Comparisons between subgroups with anti-cN1A antibody status were performed with the Mann-Whitney or Fisher’s exact tests, as appropriate.Results:Forty-nine patients with sIBM had anti-cN1A autoantibody testing, of whom 17 (34.7%) were positive. Twelve patients had muscle MRI performed (seropositivity=5). Demographics, disease duration at antibody testing and overall disease pattern were closely matched in antibody positive and negative cohorts. Dysphagia was more common in the seropositive subgroup (77% vs 47%, p=0.070). Antibody positive patients were more severely affected with a trend to lower IBM functional rating scale (IBMFRS) scores (22.4±8.4 vs 26.7±6.4, p=0.09) with significantly worse ability to climb stairs (0.9±0.9, 1.7±1.1, p=0.02). On T1-weighted MRI more fatty infiltration was found in seropositive patients (Mercuri score: 3.0±0.8 vs 1.7±0.7, p=0.03). Short tau inversion recovery (STIR) hyperintensity was more conspicuous in seropositive patients (STIR extent score: 2.4±0.6 vs 1.4±0.7, p=0.04).Conclusion:There was a trend for more dysphagia and severity of dysphagia in seropositive patients. Differences in upper limb involvement were not seen according to IBMFRS and Medical Research Council (MRC) strength grades. Seropositive patients were more severely affected at the lower limb level, in terms of muscle weakness, physical function, MRI fatty infiltration and muscle inflammation. These results suggest positive antibody status is associated with a worse phenotype. These results have potential implications in clinical trials: whether antibody status influences treatment response should be assessed.Disclosure of Interests:Revadee Dejthevaporn: None declared, Sachit Shah: None declared, Stephen Wastling: None declared, John Thornton: None declared, Tarek Yousry: None declared, Jasper M Morrow: None declared, Pedro M Machado Consultant of: PMM: Abbvie, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, Speakers bureau: PMM: Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche and UCB

Novel demonstration of conformationally modified tau in sporadic inclusion-body myositis muscle fibers

2011 ◽  
Vol 503 (3) ◽  
pp. 229-233 ◽  
Author(s):  
Anna Nogalska ◽  
Carla D’Agostino ◽  
W. King Engel ◽  
Valerie Askanas
Keyword(s):  
Inclusion Body ◽  
Inclusion Body Myositis ◽  
Muscle Fibers ◽  
Sporadic Inclusion Body Myositis

Chronic sarcoid myopathy mimicking sporadic inclusion body myositis

2019 ◽  
Vol 182 ◽  
pp. 84-86 ◽  
Author(s):  
Masayuki Miyazaki ◽  
Madoka Mori-Yoshimura ◽  
Toshiyuki Yamamoto ◽  
Yasushi Oya ◽  
Yuko Saito ◽  
...  
Keyword(s):  
Inclusion Body ◽  
Inclusion Body Myositis ◽  
Sporadic Inclusion Body Myositis
Sign in / Sign up

Export Citation Format

Share Document